OBJECTIVE: To explore the effect of Jiangtang Xiaozhi capsule (JXC) on morphological changes of islets and liver at rat model of type 2 diabetic mellitus and provide the experimental basis for the clinical therapy of type 2 diabetic mellitus. METHOD: Wister rats were fed on a diet enriched in fat and glucose to induce insulin resistan, the rats were injected intrapertoneally with a low-dose streptozotocin (STZ) twice (25 mg x kg(-1)) to induce hyperglycemia, so the successful rat model of type 2 diabetes were established. The experimental rats were divided into model group, high dose JXC group, middle dose JXC group, low dose JXC group, Erjiashuanggua group, Jinqijiangtang group and normal control group. After all the treatment groups received their own medicine for two months, all the rats were sacrificed and morphological examination on their islets and livers were performed. RESULT: Fatty liver in various degrees was seen in the model group and all the treatment groups, but the liver steatosis in middle and low dose JXC groups was significantly milder than that in model group (P < 0.05). Islets in the high dose JXC group were significantly more than that in the model group (P < 0.05). CONCLUSION: JXC can improve significantly the pathological change in islets and liver steatosis at rat model of type 2 diabetic mellitus.
OBJECTIVE: To explore the effect of Jiangtang Xiaozhi capsule (JXC) on morphological changes of islets and liver at rat model of type 2 diabetic mellitus and provide the experimental basis for the clinical therapy of type 2 diabetic mellitus. METHOD: Wister rats were fed on a diet enriched in fat and glucose to induce insulin resistan, the rats were injected intrapertoneally with a low-dose streptozotocin (STZ) twice (25 mg x kg(-1)) to induce hyperglycemia, so the successful rat model of type 2 diabetes were established. The experimental rats were divided into model group, high dose JXC group, middle dose JXC group, low dose JXC group, Erjiashuanggua group, Jinqijiangtang group and normal control group. After all the treatment groups received their own medicine for two months, all the rats were sacrificed and morphological examination on their islets and livers were performed. RESULT: Fatty liver in various degrees was seen in the model group and all the treatment groups, but the liver steatosis in middle and low dose JXC groups was significantly milder than that in model group (P < 0.05). Islets in the high dose JXC group were significantly more than that in the model group (P < 0.05). CONCLUSION: JXC can improve significantly the pathological change in islets and liver steatosis at rat model of type 2 diabetic mellitus.
Authors: Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte Journal: Mol Cell Neurosci Date: 2017-04-21 Impact factor: 4.314
Authors: Rosa Yu; Chetram Deochand; Alexander Krotow; Raiane Leão; Ming Tong; Amit R Agarwal; Enrique Cadenas; Suzanne M de la Monte Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472